Press release
Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer
-- Recommendation Based on the TROPiCS-02 Study Showing Trodelvy Demonstrated Statistically Significant and Clinically Meaningful Overall Survival in
About this update from Gilead Sciences, Inc.
[{"type":"text","content":"\n-- Recommendation Based on the TROPiCS-02 Study Showing Trodelvy Demonstrated Statistically Significant and Clinically Meaningful Overall Survival in Pre-Treated HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH–) Metastatic Breast Cancer vs. Physician’s Choice of Chemotherapy --\n\n-- This Positive Opinion Could Lead to the Second Indication Based on Overall Survival Data for Trodelvy in Metastatic Breast Cancer in Europe --\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Trodelvy® (sacituzumab govitecan) as monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting. The final European Commission decision on the additional indication for Trodelvy is anticipated later in 2023.\n\n\"This positive opinion from the Committee confirms the clinical benefit and value of sacituzumab govitecan in pre-treated HR+/HER2- metastatic breast cancer and is a positive step toward bringing this treatment option to patients in Europe,\" said Dr. Javier Cortes, Head of the International Breast Cancer Center, in Madrid and Barcelona, Spain. \"Too many people living with pre-treated HR+/HER2- metastatic breast cancer are without treatment options after their cancer progresses, and this positive opinion is a significant step forward for patients and their loved ones across Europe.\"\n\nThe CHMP positive opinion is supported by results from the Phase 3 TROPiCS-02 study, in which Trodelvy demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit of 3.2 months versus comparator single-agent chemotherapy (treatment of physician’s choice; TPC) (median OS: 14.4 months vs. 11.2 months; hazard ratio [HR]=0.79; 95% CI: 0.65-0.96; p=0.02). Trodelvy also demonstrated a 34% reduction in risk of disease progression or death (median PFS: 5.5 vs. 4.0 months; HR: 0.66; 95% CI: 0.53-0.83; p=0.0003). Three times as many people treated with Trodelvy were progression-free one year versus those treated with chemotherapy (21% vs. 7%).\n\n“When patients with HR+/HER2- metas...